New PET scan could revolutionize staging of deadly cancers

NCT ID NCT07478523

Recruiting now Diagnosis Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a new type of PET scan using a tracer called 68Ga-FAPI-46 can more accurately detect the spread of pancreatic and bile duct cancers compared to standard CT and MRI scans. The goal is to see if this scan changes how doctors classify the cancer stage and plan treatment. The trial will enroll 120 people with newly diagnosed, potentially curable cancers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 68Ga-FAPI-46 (a radioactive tracer for PET scans)
What this could lead to: If successful, this scan could become a new standard for staging these cancers, helping doctors choose the right treatment earlier and avoid unnecessary surgeries.
What could go wrong: This is a phase 2 study with 120 participants, so results are still preliminary. The new scan may not prove more accurate than current methods, and it involves radiation exposure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cholangiocarcinoma pancreatic adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHOLANGIOCARCINOMA PANCREATIC ADENOCARCINOMA

Contacts and locations

Locations

CHU de Bordeaux
RECRUITING

Pessac, 33604, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.